This is a preview of subscription content, log in via an institution to check access.
Notes
Costs were presented in 2020 US dollars, and included those for pretreatment, treatment, adverse events, subsequent salvage chemotherapy, other medical costs, and terminal care costs.
Reference
Qi CZ, et al. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States. Clinical Therapeutics : 8 Aug 2021. Available from: URL: http://doi.org/10.1016/j.clinthera.2021.06.011
Rights and permissions
About this article
Cite this article
Tisagenlecleucel appears to be cost effective for diffuse large B-cell lymphoma in the USA. PharmacoEcon Outcomes News 886, 25 (2021). https://doi.org/10.1007/s40274-021-08003-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08003-4